Cohen David E 4
4 · Evommune, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Cohen David E
Director
Transactions
- Conversion
Series Seed Preferred Stock
2025-11-07−51,588→ 0 total→ Common Stock (6,056 underlying) - Conversion
Common Stock
2025-11-07+6,056→ 23,665 total
Footnotes (1)
- [F1]Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date.